Summary: Stanford professor James Zou is reportedly raising approximately $100 million at a valuation targeting $1 billion for a startup called Human Intelligence that applies AI to research on the human body, according to Bloomberg. Zou's research includes an FDA-cleared cardiac AI (EchoNet), a Nature-published Virtual Lab that designed novel nanobodies, and a Virtual Biotech multi-agent framework that annotated 56,000 clinical trials. The deal specifics are single-source, but the researcher's credentials are among the strongest in AI-biology, and the funding environment, $11 billion into AI drug discovery in Q1 2026 alone, is historically accommodating.
James Zou has spent the past decade building AI systems that do science. His Virtual Lab, published in Nature in July 2025, assembled a team of large language model agents led by an AI principal investigator that designed 92 novel nanobody binders against SARS-CoV-2 variants, two of which showed improved binding in experimental validation. His Virtual Biotech, posted as a preprint in February 2026, created a multi-agent framework mimicking a pharmaceutical company's hierarchy with 11 specialised agents that spawned 37,000 sub-agents to annotate nearly 56,000 clinical trials, finding that drugs targeting cell-type-specific genes are 48% more likely to reach market and show 32% lower adverse event rates. His EchoNet, a deep learning model for cardiac function assessment from echocardiograms, was cleared by the FDA after a blinded randomised clinical trial showed it outperformed human sonographers. Now, according to Bloomberg, Zou is raising approximately $100 million at a valuation targeting $1 billion for a startup called Human Intelligence that will apply AI to research on the human body. The company name, valuation, and raise amount have not been independently confirmed, but the research behind them is among the most credible in the field.
The researcher
Zou is an associate professor of biomedical data science at Stanford, with courtesy appointments in computer science and electrical engineering. He completed his PhD at Harvard in 2014, studied at Cambridge as a Gates Scholar, held a Simons fellowship at Berkeley, and joined Stanford's faculty in 2016. He has received two Chan-Zuckerberg Biohub Investigator Awards, a Sloan Fellowship, an NSF CAREER Award, and faculty research awards from Google, Adobe, and Amazon. He sits on Amgen's scientific advisory board. Eric Topol, the Scripps Research cardiologist and one of the most widely read voices in medical AI, has called Zou “one of the most prolific and creative A.I. researchers in both life science and medicine.” His lab has produced or advised more than ten companies, including Gradio, the open-source machine learning demonstration library used by over a million developers, which was acquired by Hugging Face in 2021.
What distinguishes Zou's work from the broader AI-in-healthcare field is its scope. Most AI health startups are built around a single application: a diagnostic model, a drug target predictor, a clinical trial optimiser. Zou's research spans all of these. The Virtual Lab designs molecules. EchoNet reads echocardiograms. SyntheMol, published in Nature Machine Intelligence, generates novel small molecules targeting antibiotic-resistant bacteria and was named a New York Times “2024 Good Tech” project. The through line is not a single product but a methodological claim: that AI agents, structured as virtual research teams, can accelerate the entire arc of biomedical discovery, from identifying a target to designing a molecule to predicting its clinical outcome. Human Intelligence, if the Bloomberg report is accurate, appears to be the commercial vehicle for that claim.
The market
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!
The US AI-in-healthcare market was valued at $18.1 billion in 2025 and is projected to reach $223 billion by 2033, according to Grand View Research. AI-enabled drug discovery and diagnostics raised $11 billion in the first quarter of 2026 alone. Global venture capital hit $297 billion in Q1 2026, an all-time record, with AI capturing approximately 80% of the total. Forty-seven new unicorns were minted in the quarter. The funding environment for an AI-biology startup led by a Stanford professor with Nature publications, an FDA-cleared product, and a decade of research is, to put it mildly, accommodating.
The comparable that matters most is Fei-Fei Li's World Labs, another Stanford AI spinout, which reached a $1 billion valuation within four months of its founding in 2024 and is now reportedly valued above $10 billion. Its initial round of approximately $100 million was led by NEA. The parallels are structural: a Stanford professor with a body of foundational research starts a company, and the market prices the company not on revenue, which does not yet exist, but on the researcher's track record and the breadth of the technology's potential applications. Anthropic's $400 million acquisition of a biotech AI startup called Coefficient Bio, which had fewer than ten employees and no disclosed product when it was acquired in an all-stock deal, illustrates how aggressively the market is valuing AI-biology talent. Coefficient Bio's co-founders came from Genentech's computational drug discovery unit. Zou comes from Stanford's medical school. The valuation logic is the same: the team is the product.
The competition
The field Zou is entering is not empty. Xaira Therapeutics has raised $1.3 billion. Isomorphic Labs, the DeepMind spinoff led by Nobel laureate Demis Hassabis, raised 508 million euros and signed nearly $3 billion in partnerships with Eli Lilly and Novartis, with Isomorphic Labs pushing AI-designed drugs toward human trials this year. Recursion Pharmaceuticals absorbed Exscientia to consolidate its public-market position. Insilico Medicine, which produced the first AI-discovered drug to reach a Phase II clinical trial, filed for a Hong Kong Stock Exchange listing in December 2025. Hippocratic AI reached a $1.64 billion valuation. OpenEvidence raised $210 million at $3.5 billion. The AI drug discovery and digital health sectors are crowded, well-funded, and moving fast.
What none of these competitors has done is demonstrate that AI can reliably replace the core scientific judgment that drives drug development from target to patient. AI health tech is booming but cures remain elusive: the FDA has cleared 295 AI medical devices in a single year, but no AI-discovered drug has completed a pivotal Phase III trial. The defining tension in the field is the gap between what AI can do in a laboratory and what it has delivered to patients. Most AI health companies address one slice of the pipeline. Zou's pitch, judging by his published research, is that his approach addresses the pipeline itself, that multi-agent AI systems structured as virtual research organisations can compress timescales across discovery, design, and clinical prediction simultaneously. Whether that pitch justifies a $1 billion valuation for a company with no disclosed revenue or product depends on whether one believes the bottleneck in drug development is scientific labour, which AI can automate, or regulatory, institutional, and biological complexity, which it cannot.
The context
The biggest technology companies in the world have decided that AI and human health belong together. Microsoft's entry into AI-powered personal health with Copilot Health in March 2026 aggregates wearable data and electronic health records into a single AI-driven interface for consumers. OpenAI launched ChatGPT Health in January. Anthropic unveiled Claude for Healthcare the same week as Microsoft. Google DeepMind's AlphaFold has been cited in thousands of papers and underpins Isomorphic's drug design engine. The market validation for AI applied to human physiology is no longer speculative. The question is whether a startup can capture value in a space where the platform companies are arriving with billions in capital and billions of users.
WHOOP's $10 billion valuation as a health data platform, reached through a $575 million Series G that closed in March 2026, shows that companies built around continuous physiological data can command extraordinary valuations even before going public. WHOOP has 2.5 million members and a bookings run rate of $1.1 billion. It collects heart rate, heart rate variability, blood pressure, and sleep data, then layers AI insights on top. The wearable-to-AI pipeline it represents is the consumer-facing version of what Zou's research tackles from the scientific side: making sense of physiological signals at scale. The difference is that WHOOP has revenue, customers, and an FDA-cleared ECG. Human Intelligence, as far as public information indicates, has a Stanford professor and a body of research. In the current market, that may be enough to raise $100 million at a billion-dollar valuation. Whether it is enough to build a company that changes how medicine is done is a question that no amount of venture capital can answer in advance. It is a question that only data from human bodies, not AI models trained on them, will eventually resolve.